Patient-reported measures: how useful in health economics?

Anne-Gaëlle Le Corroller¹, Julia Bonastre^{2

3}

Affiliations

¹ INSERM, IRD, SESSTIM, Aix Marseille University, Marseille, France.
² Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Julia.bonastre@gustaveroussy.fr.
³ Oncostat CESP, INSERM 1018, UVSQ, Labeled Ligue Contre Le Cancer, Université Paris-Saclay, Villejuif, France. Julia.bonastre@gustaveroussy.fr.

Editorial

Anne-Gaëlle Le Corroller et al. Eur J Health Econ. 2023 Feb.

. 2023 Feb;24(1):1-4.

doi: 10.1007/s10198-022-01524-z. Epub 2022 Nov 8.

Anne-Gaëlle Le Corroller¹, Julia Bonastre^{2

3}

¹ INSERM, IRD, SESSTIM, Aix Marseille University, Marseille, France.
² Bureau Biostatistique et Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Julia.bonastre@gustaveroussy.fr.
³ Oncostat CESP, INSERM 1018, UVSQ, Labeled Ligue Contre Le Cancer, Université Paris-Saclay, Villejuif, France. Julia.bonastre@gustaveroussy.fr.

No abstract available

Comment on

A systematic review of the validity and reliability of patient-reported experience measures.
Bull C, Byrnes J, Hettiarachchi R, Downes M. Bull C, et al. Health Serv Res. 2019 Oct;54(5):1023-1035. doi: 10.1111/1475-6773.13187. Epub 2019 Jun 19. Health Serv Res. 2019. PMID: 31218671 Free PMC article.

1. Meadows, K.A.: Patient-reported outcome measures: an overview. Br. J. Commun. Nurs. 16(3), 146–151 (2011) - DOI
1. DeMuro, C., Clark, M., Doward, L., Evans, E., Mordin, M., Gnanasakthy, A.: Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value Health 16(8), 1150–1155 (2013) - DOI
1. Gnanasakthy, A., Barrett, A., Evans, E., D’Alessio, D., Romano, C.D.: A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012–2016). Value Health 22(2), 203–209 (2019) - DOI
1. Marquis, P., Caron, M., Emery, M.-P., Scott, J.A., Arnould, B., Acquadro, C.: The role of health-related quality of life data in the drug approval processes in the US and Europe. Pharm. Med. 25, 147–160 (2011) - DOI
1. FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. In: Research CfDEa (ed.) (2019).